Medtronic India Launches Cryoablation Catheter to Treat Atrial Fibrillation Patients, Health News, ET HealthWorld
Cryoballoon catheter ablation is a minimally invasive procedure and one of the therapeutic modalities for managing AF. It is designed to block unwanted electrical signals from the pulmonary veins (large blood vessels that carry blood from the lungs to the left atrium of the heart) and spreading to the theater (the upper chambers of the heart). This is done with a technique known as pulmonary vein isolation which targets the tissue where the veins and atria connect and prevents the spread of unwanted electrical signals.
The procedure using the Central Drugs Standard Control Organization (CDSCO) approved cryoballoon catheter was performed by Dr Balbir Singh, Chairman, Department of Cardiology, Pan Max Hospital, Saket, Delhi.
Medtronic’s cryoballoon catheter targets pulmonary vein isolation to prevent unwanted electrical signals from spreading through the body, effectively treating AF. It has been found to be effective and safe by various regulatory authorities, and is further used to treat over one million patients around the world.
Elucidating the technique, Madan Krishnan, Vice President and General Manager of Medtronic India, said: “Cryoballoon ablation is a minimally invasive procedure that offers short recovery time and comparable safety and efficacy to radiofrequency therapy. standard, but with the advantage of higher processing efficiency. In collaboration with leading clinicians, researchers and scientists around the world, Medtronic offers the broadest range of innovative medical technologies for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias ”,
AF, which has affected nearly 60 million people worldwide, is an irregular heartbeat that affects the upper chambers (atria) of the heart. The heart of a person diagnosed with AF beats up to 300 times per minute or more in the atria and up to 150 times per minute or more in the lower chambers (ventricles) compared to a normal heart which beats about 60 to 100 times per minute.
It has further been linked to serious health complications, including heart failure, stroke, and increased risk of death. India has relatively higher death rates and younger patients with AF compared to their Western counterparts. Two-thirds of the total number of patients with AF suffer from persistent or permanent AF, which contributes to a higher number of deaths in the country.
Commenting on how cryoballoon ablation can provide safer treatment and a better quality of life, Dr Singh said, “AF is a progressive disease, which means that over time, patients can experience severe disease. more frequent and longer episodes. Cryoballoon ablation is a safe and effective treatment before or after drug therapy to control atrial fibrillation. By treating patients with the most advanced and clinically relevant technology, we are better equipped to successfully manage their atrial fibrillation, thereby improving their overall quality of life. “
Medtronic had previously received US Food and Drug Administration (FDA) approval for the Arctic Front ™ family of cardiac cryoablation catheters to treat recurrent symptomatic paroxysmal atrial fibrillation (episodes that last less than seven consecutive days) as alternative to antiarrhythmic drugs (AAD) therapy for the initial rhythm control strategy. It can help in the treatment of the disease at the stage of progression, thus improving the therapeutic effectiveness.